CDKN2A and acute lymphoblastic leukemia: In contrast, increased rates of CDKN2A/B deletions are found in Ph+ ALL with a reported frequency of ~50% (80, 92, 136) compared to around 30% in non-Ph+ B-ALL (137, 138).